Novartis (NVS +0.3%) gives an upbeat prognosis about its pipeline ahead of its investor day, predicting that it could produce at least 14 "blockbuster" drugs within five years and help offset the the expiry of patents on existing top-earning treatments. The most promising drugs include LCZ686 and serelaxin for heart failure despite the latter's mixed Phase III trial, as well as medicines for psoriasis and multiple sclerosis.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Zacks.com (Tue, 4:13PM)
at Investor's Business Daily (Mon, 4:49PM)
at Benzinga.com (Mon, 11:34AM)
at Investor's Business Daily (Jan 26, 2015)
at Nasdaq.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs